AllPeptides.eu - Advanced Peptide Research
    Single Peptides
    Fertility

    HMG (Human Menopausal Gonadotropin) (75 IU)

    Subcutaneous / Intramuscular3 times weekly75 IU

    Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16

    🇺🇸 FDA (Menopur®)
    🇪🇺 EMA (Menopur®)

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    FDA & EMA approved — for specific indications
    Educational information. Not medical advice or a recommendation for use.

    ⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer

    Free Access

    How It Works

    HMG provides exogenous FSH and LH. FSH stimulates Sertoli cells for spermatogenesis, while LH stimulates Leydig cells to produce testosterone. The combination is essential for complete spermatogenesis.

    Quick Start

    • Reconstitution: Add 1.0 mL of bacteriostatic water → 75 IU/mL.
    • Typical dose: 75 IU 3 times weekly.
    • Storage: 2–8 °C after reconstitution.
    Detailed Protocol Data

    Dosing Table — HMG 75 IU

    Educational only

    Route: Subcutaneous / Intramuscular | Frequency: 3 times weekly

    WeekDoseUnits (per injection)
    Weeks 1–12+
    75 IU
    100 units (1.00 mL) × 3/week

    Studies report administration 75 IU three times weekly. It is often combined with HCG for full fertility support.

    Related compounds

    Reconstitution Steps

    1. Withdraw 1.0 mL of bacteriostatic water.
    2. Slowly inject into the vial.
    3. Swirl gently.
    4. Refrigerate at 2–8 °C.

    Protocol Overview

    • Goal: Stimulation of spermatogenesis via FSH + LH action.
    • Schedule: 75 IU × 3/wk for 3–6 months.
    • Combination: Often with HCG 1,000–1,500 IU × 2–3/wk.

    Dosing Protocol

    • Typical Dose: 75 IU × 3/wk.
    • Duration: 3–6 months, evaluate with a semen analysis.
    • Combination: HCG + HMG for optimal results.
    • Break between cycles: After the cycle (3–6 months), a pause of 4–8 weeks and evaluation via semen analysis is recommended before restarting.

    Washout & Cycle Restart

    When can I restart?

    After the cycle (3–6 months), a pause of 4–8 weeks and evaluation via semen analysis is recommended before restarting.

    Minimum wait period: 4 weeks

    Storage Instructions

    • Lyophilized: 2–8 °C.
    • Reconstituted: 2–8 °C · use immediately or within 24 hours.

    Important Notes

    • Requires medical monitoring of hormones.
    • Spermatogenesis takes 3+ months to show results.
    • Use sterile technique.
    Clinical Analysis & Safety

    Potential Benefits & Side Effects

    Potential Benefits:

    • Stimulation of spermatogenesis.
    • Fertility support in hypogonadism.
    • Synergistic action of FSH + LH.

    Potential Side Effects:

    • Possible local reaction at the injection site.
    • Rare gynecomastia at high doses.
    • Requires estradiol monitoring.

    ⚠️ Serious Warnings & Long-Term Risks

    The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.

    🧬 Endocrine
    🔴 High Risk

    OHSS & multiple pregnancies

    HMG (Menopur®) can cause severe OHSS and multiple pregnancies. Requires medical monitoring with ultrasound.

    📄 FDA Label — Menopur®

    References

    1. Journal of Clinical Endocrinology — HMG for male infertility
      View Source
    2. Human Reproduction — FSH/LH therapy and spermatogenesis
      View Source

    Recommended Supplements

    Research Sources & Verified Data
    …
    Clinical Trials
    …
    PubMed Studies
    Approved
    FDA Status
    2
    Regulatory Approvals
    Verified across ClinicalTrials.gov, PubMed & FDA

    External Sources & Regulatory Status

    Regulatory Approvals

    🇺🇸
    FDA
    Approved

    Menopur® · Infertility (1996)

    🇪🇺
    EMA
    Approved

    Menopur® · Infertility

    FDA + EMA approved

    No official regulatory source available yet — research peptide.

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Summary:
    2 Approvals
    0 PubMed
    0 Clinical Studies

    Continue Your Research

    Explore tools and guides related to this protocol.

    Educational contentRegularly reviewed & maintainedEvidence-based review

    Important Disclaimer

    The content of this website is provided exclusively for informational and educational purposes within the context of research literature.

    Read the full Disclaimer →

    Educational Navigator

    Educational reading navigator

    Find where to start in research peptide science through evidence, safety context and regulatory awareness.

    Covers

    Evidence levelsSafety contextRegulatory overviewLiterature readingResearch methodEducational reports
    5 min readEvidence-firstOpen access
    Open evidence framework

    New knowledge, new tools and selected updates from AllPeptides.eu